Genprex Links Low TROP2 to Reqorsa Resistance in Lung Cancer Models
Austin – November 04, 2026 -- Genprex, Inc. (NASDAQ: GNPX) reported that low TROP2 expression was consistently associated with primary resistance to its lead gene therapy Reqorsa (quaratusugene ozeplasmid) across multiple preclinical non-small cell lung cancer (NSCLC) models. The company says the finding could guide patient selection in future trials.
About half of tested NSCLC models showed primary resistance
Approximately 50% of 10 NSCLC cell lines and 50% of 12 patient-derived organoid models showed primary resistance to TUSC2 gene delivery. Protein-expression analyses identified low TROP2 expression as a marker associated with that resistance.
Patient biopsies from a TUSC2 trial back the association
Analysis of pretreatment tumor biopsies from patients enrolled in a TUSC2 gene therapy clinical trial supported the link between TROP2 expression and treatment response. The company did not disclose patient numbers or effect sizes.